BHC: Bausch Health Companies Inc. Stock

by  •  • Comments Off on BHC: Bausch Health Companies Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 2,640.83
Enterprise Value ($M) 24,032.83
Book Value ($M) -242.00
Book Value / Share -0.66
Price / Book -10.91
NCAV ($M) -21,071.00
NCAV / Share -57.29
Price / NCAV -0.13

Profitability (mra)
Return on Invested Capital (ROIC) -0.00
Return on Assets (ROA) -0.00
Return on Equity (ROE) n/a

Liquidity (mrq)
Quick Ratio 0.62
Current Ratio 0.86

Balance Sheet (mrq) ($M)
Current Assets 5,774.00
Assets 26,523.00
Liabilities 26,845.00
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 9,625.00
Operating Income 1,976.00
Net Income -46.00
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 1,597.00
Cash from Investing -454.00
Cash from Financing -868.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
08-30 13G Meruelo Alex 9.97
08-19 13D/A Icahn Carl C
2024-02-13 13G/A Goldentree Asset Management Lp 7.80 44.02

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-02-20 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SE
2024-10-31 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2024 OR ☐ TRANSITION REPORT PURSU
2024-08-01 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT T
2024-05-02 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-02-21 476,540 2,798,339 17.03
2025-02-20 959,216 5,717,881 16.78
2025-02-19 560,937 2,426,343 23.12
2025-02-18 491,744 2,302,491 21.36

(click for more detail)

Similar Companies
ADCT – ADC Therapeutics SA ANRO – Alto Neuroscience, Inc.
ANVS – Annovis Bio, Inc. BHVN – Biohaven Ltd.
BMY – Bristol-Myers Squibb Company


Financial data and stock pages provided by
Fintel.io

Finpedia: Bausch Health